Cargando…
Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor modified T cell infusions for liver metastases
INTRODUCTION: Our phase I Hepatic Immunotherapy for Metastases (HITM) trial tested the safety of chimeric antigen receptor modified T cell (CAR-T) hepatic artery infusions (HAI) for unresectable CEA+ liver metastases (LM). High neutrophil:lymphocyte ratios (NLR) predict poor outcome in cancer patien...
Autores principales: | Saied, Abdul, Licata, Lauren, Burga, Rachel A., Thorn, Mitchell, McCormack, Elise, Stainken, Brian F., Assanah, Earle O., Khare, Pranay D., Davies, Robin, Espat, N. Joseph, Junghans, Richard P., Katz, Steven C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245365/ https://www.ncbi.nlm.nih.gov/pubmed/25277132 http://dx.doi.org/10.1038/cgt.2014.50 |
Ejemplares similares
-
Evaluation of the neutrophil:lymphocyte ratio as an indicator of chronic distress in the laboratory mouse
por: Hickman, Debra L
Publicado: (2017) -
Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor
por: Katz, Steven C, et al.
Publicado: (2013) -
Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival
por: Cummings, M, et al.
Publicado: (2015) -
Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery
por: Katz, Steven, et al.
Publicado: (2016) -
Neutrophil:lymphocyte ratio predicts short-term outcome of COVID-19 in haemodialysis patients
por: Mutinelli-Szymanski, Prisca, et al.
Publicado: (2020)